Article

Cellular and humoral immunity towards parental SARS-CoV-2 and variants of concern after two doses of the NVX-CoV2373-vaccine in comparison to homologous BNT162b and mRNA1273 regimens

2022-08-03

Abstract excerpt

The NVX-CoV2373-vaccine has recently been licensed, although data on vaccine-induced humoral and cellular immunity towards the parental strain and variants of concern (VOCs) in comparison to dual-dose mRNA-regimens are limited. In this observational study including 66 participants, we show that NVX-CoV2373-induced IgG-levels were lower than after vaccination with BNT162b2 or mRNA-1273 (n=22 each, p=0.006). Regardl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0b42c6fe-2ff0-5b5f-b91a-c1460b88a773
DOI: 10.1101/2022.08.02.22278342

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cellular and humoral immunity towards parental SARS-CoV-2 and variants of concern after two doses of the NVX-CoV2373-vaccine in comparison to homologous BNT162b and mRNA1273 regimensDOI 10.1101/2022.08.02.22278342Read

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccinesSemantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipientsSemantic proximity Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity Read

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.Semantic proximity Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Immune responses of the third dose of AZD1222 vaccine or BNT162b2 mRNA vaccine after two doses of CoronaVac vaccines against Delta and Omicron variantsSemantic proximity Read

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsSemantic proximity Read

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trialSemantic proximity Read

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read